Randomized trial · people
Semaglutide STEP 4: -7.9% weight vs +6.9% after switch to placebo
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, people who stopped semaglutide after 20 weeks regained weight, while those who stayed on it kept losing.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 803
- Published
- 2021
- Journal
- JAMA
What they tested
After 20 weeks on semaglutide, does staying on it keep weight off better than switching to a placebo (a dummy shot)?
How the study was done
A randomized, double-blind, placebo-controlled phase 3a withdrawal trial at 73 sites in 10 countries. All 902 adults with overweight or obesity and no diabetes first took weekly semaglutide for 20 weeks, building up to 2.4 mg. The 803 who reached that dose were then split 2:1 to keep taking it or switch to placebo for 48 more weeks, with lifestyle support in both groups.

Model. Individual results vary.
What they found
During the first 20 weeks on semaglutide, people lost 10.6% of their body weight on average. Over the next 48 weeks, weight changed by -7.9% in those who kept taking semaglutide and by +6.9% in those switched to placebo, a difference of -14.8 percentage points. Staying on semaglutide also improved waist size (-9.7 cm), systolic blood pressure, the top number (-3.9 mm Hg), and a physical functioning score (2.5 points) compared with placebo. Stomach and gut side effects were more common on semaglutide (49.1% vs 26.1%), but similar shares stopped treatment because of side effects (2.4% vs 2.2%).
What it doesn’t show
Only people who handled the full 2.4 mg dose during the first 20 weeks were randomized, and people with diabetes were excluded. The comparison covers 48 weeks after the switch, so it doesn't show what happens over a longer time.
The paper
Rubino et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
The compound
More studies on Semaglutide
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetesRandomized trial · people · 2025
- Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4Randomized trial · people · 2025
- Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeksRandomized trial · people · 2025
- Every study on Semaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.